3-V Biosciences doses first patient with fatty acid inhibitor for NASH

3-V Biosciences dosed its first patient in a phase 2 clinical trial of a fatty acid inhibitor candidate from Ascletis for the treatment of nonalcoholic steatohepatitis, according to a press release.
“Lipid synthesis is an important driver of NASH,” Rohit Loomba, MD, from the University of California San Diego, and coordinating investigator of the phase 2 study, said in the release. “The imaging techniques in this study will give us a very clear understanding of the impact this drug has on liver fat, a key driver of this disease.”
TVB-2640 is an orally bioavailable

Source link

Related posts

Author Correction: A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip


Change in eating pattern as a contributor to energy intake and weight gain during the winter holiday period in obese adults


Dealing With Cancer in the 'Oldest Old' Patients


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy